Company intelligence / Profile preview
Alephoson Biopharmaceuticals Limited
Hong Kong, Hong Kongalephoson.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Currently completing preclinical toxicity studies for their eye drop delivery system, with plans to request FDA authorization for Phase 1 and 2a trials by Q1 2026
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Peptide-drug conjugatesCell-penetrating peptidesBiologics
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Uni-Bio Science Group LimitedUniversity hospitals in Hong Kong, mainland China, Asia and the United States
Beyond the preview
Go deeper on Alephoson Biopharmaceuticals Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alephoson Biopharmaceuticals Limited.